Evidence map›Paper›PMID 39439530›Full record

ArticleEuropean heart journal open2024

Health-related quality of life with rivaroxaban plus aspirin vs. aspirin alone in chronic stable cardiovascular disease: Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) trial.

Feng Xie, Jiajun Yan, John Eikelboom, Sonia Anand, Eva Muehlhofer, Eleanor Pullenayegum, Yang Wang, Alvaro Avezum, Deepak L Bhatt, Salim Yusuf and 1 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European heart journal open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01776424 (A Randomized Controlled Trial of Rivaroxaban for the Prevention of Major Cardiovascular Events in Patients With Coronary or Peripheral Artery Disease), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01776424 phase3completednot on this map

A Randomized Controlled Trial of Rivaroxaban for the Prevention of Major Cardiovascular Events in Patients With Coronary or Peripheral Artery Disease (COMPASS - Cardiovascular OutcoMes for People Using Anticoagulation StrategieS).

TypeinterventionalSponsorBayerRan2013 to 2021Enrolled27,395ConditionsPrevention & ControlArmsRivaroxaban (Xarelto, BAY59-7939), Aspirin, Aspirin placebo, Rivaroxaban placebo, Pantoprazole
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Feng XieDepartment of Health Research Methods, Evidence, and Impact, Faculty of Health Sciences, McMaster University, 1280 Main Street West, Hamilton, Ontario, Canada L8S 4L8.ORCID https://orcid.org/0000-0003-3454-6266
Jiajun YanDepartment of Health Research Methods, Evidence, and Impact, Faculty of Health Sciences, McMaster University, 1280 Main Street West, Hamilton, Ontario, Canada L8S 4L8.
John EikelboomPopulation Health Research Institute, McMaster University, Hamilton Health Sciences, Hamilton, Ontario, Canada L8L 2X2.
Sonia AnandPopulation Health Research Institute, McMaster University, Hamilton Health Sciences, Hamilton, Ontario, Canada L8L 2X2.ORCID https://orcid.org/0000-0003-3692-7441
Eva MuehlhoferResearch and Development, Pharmaceuticals TA Thrombosis, Bayer AG, Wuppertal, 42113, Germany.
Eleanor PullenayegumChild Health Evaluative Sciences, Hospital for Sick Children, Toronto, Ontario, Canada M5G 1X8.
Yang WangDepartment of Health Research Methods, Evidence, and Impact, Faculty of Health Sciences, McMaster University, 1280 Main Street West, Hamilton, Ontario, Canada L8S 4L8.
Alvaro AvezumInstituto Dante Pazzanese de Cardiologia, Sao Paulo, 04012-180, Brazil.ORCID https://orcid.org/0000-0002-3073-6890
Deepak L BhattMount Sinai Heart, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.ORCID https://orcid.org/0000-0002-1278-6245
Salim YusufPopulation Health Research Institute, McMaster University, Hamilton Health Sciences, Hamilton, Ontario, Canada L8L 2X2.ORCID https://orcid.org/0000-0003-4776-5601
Jackie BoschPopulation Health Research Institute, McMaster University, Hamilton Health Sciences, Hamilton, Ontario, Canada L8L 2X2.ORCID https://orcid.org/0000-0001-6292-4207

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aims: This study aimed to compare the effects of the combination of rivaroxaban and aspirin with aspirin alone on health-related quality of life in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) trial. Methods and results: Health-related quality of life assessed using the EQ-5D-3L. The treatment effects on health utility and EQ visual analogue scale (EQ VAS) scores were compared between rivaroxaban plus aspirin and aspirin alone in terms of adjusted mean difference in change from baseline and odds ratio of having deterioration events. Nine thousand forty-nine (98.9%) and 6916 (75.5%) completed the EQ-5D-3L at baseline and at final visit, respectively. Nine thousand twenty-eight (98.9%) and 6887 (76.3%) completed the EQ-5D-3L at baseline and final visit, respectively. Mean (standard deviation) health utility and EQ VAS scores at baseline were 0.871 (0.141) and 76.0 (15.3), respectively, for the rivaroxaban plus aspirin group, compared with 0.873 (0.139) and 75.8 (15.1) for the aspirin group. Adjusted mean difference in change from baseline utility was -0.002 [95% confidence interval (CI), -0.006, 0.002, Conclusion: This analysis of the COMPASS trial demonstrated that the quality of life of patients was similar between the rivaroxaban plus aspirin group and the aspirin alone group. Registration: Trial registration number: ClinicalTrials.gov number (NCT01776424). Trial protocol and statistical analysis plan: https://www.nejm.org/doi/full/10.1056/NEJMoa1709118#APPNEJMoa1709118PRO.

Indexed as

AnticoagulationCardiovascular diseaseEQ-5DHealth-related quality of lifePatient-reported outcomes

Identifiers

PMID39439530
PMCPMC11495100

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.